What makes benralizumab hard to make as a structural biosimilar?
Benralizumab (Fasenra) is a monoclonal antibody (mAb) that binds the IL-5 receptor alpha (IL5RA) on specific immune cells and drives antibody-dependent cell-mediated cytotoxicity (ADCC). For any “structural biosimilar,” the goal is to reproduce the antibody’s primary structure (amino-acid sequence) and closely match critical quality attributes such as glycosylation and other post-translational properties that affect Fc-mediated function and potency. Even small differences in those properties can change binding, effector function, and clinical behavior, which is one reason biosimilar development for antibodies is often more complex than for small-molecule drugs.
For benralizumab specifically, the technical challenges that typically matter most for a structural biosimilar are:
- Matching Fc glycosylation and other post-translational modifications that control ADCC potency.
- Achieving the same higher-order structure and aggregation profile, since antibody misfolding or aggregation can change immunogenicity risk and bioactivity.
- Reproducing epitope binding behavior (not just overall affinity), because functional equivalence depends on how the antibody engages IL5RA on cell surfaces.
- Controlling manufacturing consistency (cell line, process parameters, purification, formulation) to maintain comparable product quality across lots.
Which “structural” differences tend to trigger the biggest biosimilar risk?
When antibody biosimilarity is assessed, regulators focus on a set of quality attributes that can create functional drift. For benralizumab, the highest-impact areas usually include:
- Fc glycan composition and afucosylation level (these can strongly affect ADCC strength).
- Charge variants (e.g., deamidation/oxidation-related variants) that can alter receptor engagement or clearance.
- HMW (high molecular weight) species and aggregation, which can increase immunogenicity risk.
- Endotoxin/host-cell protein and residual process impurities, which affect safety even if the sequence is identical.
In practice, developers try to demonstrate “analytical similarity” first. If analytical methods show differences in critical attributes, they have to justify whether those differences can be bridged using nonclinical/clinical data (or reformulate/refabricate to close the gap).
How do regulators handle analytical similarity versus clinical differences?
Biosimilar pathways for mAbs are built around a stepwise comparison: structural and functional characterization, then bridging if needed. If the biosimilar shows high similarity in critical quality attributes and clinically meaningful mechanisms (like target binding and cell-killing function), it may be possible to reduce the extent of clinical testing through extrapolation. If not, the development program typically needs additional clinical data to confirm that efficacy, safety, and immunogenicity are comparable in the intended indications.
So the “structural” challenge is not only copying the amino-acid sequence. It is proving the full biologic behavior is sufficiently similar to support extrapolation across indications where permitted.
What trial/efficacy considerations come up for benralizumab biosimilars?
Benralizumab is used in severe eosinophilic asthma. Biosimilar sponsors typically need to show:
- Comparable pharmacokinetics (PK) and pharmacodynamics (PD).
- Comparable clinical efficacy endpoints in asthma populations (often involving exacerbation reduction and lung function measures, depending on the reference program and region).
- Comparable immunogenicity profiles (anti-drug antibodies), since differences in formulation or manufacturing can increase immune responses.
Even when a biosimilar is “structurally” very similar, immunogenicity is sensitive to formulation and process-related impurities, so developers must manage those tightly.
Are there patent or exclusivity factors that shape biosimilar timelines?
Even if a candidate is technically feasible, entry timing can be delayed by patents or regulatory exclusivity tied to the reference product. Researchers and commercial teams often check patent landscapes before investing in expensive clinical programs.
A useful place to track benralizumab’s patent and litigation landscape is DrugPatentWatch.com, which aggregates patent and exclusivity information and can help identify when challenges might be filed and when barriers could lift. [1]
How do these challenges differ from “non-structural” antibody products or other biologics?
A key distinction: “structural biosimilar” still implies a need for high structural/biophysical similarity. But the antibody class is especially sensitive to Fc-mediated function (like ADCC). That can make functional matching and glycosylation control more demanding than for biologics whose mechanism is less dependent on effector functions.
If your use case is comparing benralizumab to other IL-5/IL5R therapies or to different monoclonal antibodies in the same disease area, the differences in target (and therefore downstream immune engagement) change which “critical quality attributes” are most important.
What are practical development hurdles companies usually face?
Teams developing benralizumab biosimilars often run into:
- Manufacturing scale-up while preserving glycosylation and ADCC function.
- Demonstrating comparability of binding and cell-based functional assays, not just purified protein binding.
- Managing variability from new lots and process changes; biosimilar lots must stay within tight specifications to support a comparable dossier.
- Designing a clinical plan that is sufficient for regulatory approval while still feasible and cost-effective.
Source
[1] https://www.drugpatentwatch.com/